modelOxymorphone
Extends from Pharmacolibrary.Drugs.ATC.N.N02AA11.
Information
| name: | Oxymorphone | |
| ATC code: | N02AA11 | route: | oral |
| compartments: | 1 | |
| dosage: | 10 | mg |
| volume of distribution: | 2.65 | L |
| clearance: | 0.58 | L/min |
| other parameters in model implementation | ||
Oxymorphone is a potent semi-synthetic opioid analgesic used for the management of moderate to severe pain. It acts primarily as a mu-opioid receptor agonist and is available in both immediate-release and extended-release oral formulations, as well as parenteral forms. Oxymorphone is approved for clinical use but is a controlled substance due to its abuse potential.
Pharmacokinetics
Pharmacokinetic parameters reported in healthy adult subjects (both males and females), under fasting conditions, following a single oral immediate-release dose.
References
Agema, BC, et al., & Koolen, SLW (2021). Population Pharmacokinetics of Oxycodone and Metabolites in Patients with Cancer-Related Pain. Cancers 13(11) –. DOI:10.3390/cancers13112768 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34199534
Sloan, PA, & Barkin, RL (2008). Oxymorphone and oxymorphone extended release: a pharmacotherapeutic review. Journal of opioid management 4(3) 131–144. DOI:10.5055/jom.2008.0018 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18717508
Benedek, IH, et al., & Fiske, WD (2011). Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release. Drug design, development and therapy 5 455–463. DOI:10.2147/DDDT.S24372 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22162639
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)